Trial · NCT00674570
Veteran Stress and Learning Study
NCT00674570, Phase 4, Completed, VA Office of Research and Development; results first posted 2019-05-30
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Veteran Stress and Learning Study. Trials, record NCT00674570. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00674570
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Veteran Stress and Learning Study
- NCT number
- NCT00674570
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 111 participants, actual
- Lead sponsor
- VA Office of Research and Development
- Conditions
- Stress Disorders, Posttraumatic
- Interventions
- Hydrocortisone, D-Cycloserine, Placebo
- First posted
- 2008-05-08
- Last updated
- 2019-05-30
- Results first posted
- 2019-05-30
- Limitations and caveats
Technical difficulties rendered corrugator electromyogram data unusable for analysis. We selected skin conductance as a primary measure of sympathetic activity rather than heart rate, which has both sympathetic and parasympathetic influences.
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of Maximum Skin Conductance Response (SCR) in Microsiemens (µS) | 15 minute measurement intervals on Study Days 7, 9, and 16 | Psychophysiology measurements occurred on day 7 for fear conditioning, day 9 for fear extinction, and day 11 for extinction retention. The primary outcome measures are presented for the first and last conditioned stimulus (CS) trials during fear conditioning and extinction and for the first 2 trials during retention. Conditioned Responses (CR): An SCR score was obtained for each CS by subtracting the mean skin conductance level (SCL) in microsiemens (µS) for the 2-s interval immediately preceding CS onset from the max SC level in µS during the 8-s CS presentation. Unconditioned Response (UCR): An SCR score for the UCR was obtained by subtracting the mean SCL in µS within 6-8 s following CS offset from the max increase in SC level during the .5-6.5 time interval following the CS offset, corresponding to the onset of the .5s US. SC responses were range corrected using each participant's maximum response to the UCS or CS during acquisition trials of the fear conditioning phase. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Proportion of Maximum Skin Conductance Response (SCR) in Microsiemens (µS) | 15 minute measurement intervals on Study Days 7, 9, and 16 | proportion of max SCR (µS) | MEAN |
Source ClinicalTrials.gov
Results by group15
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Proportion of Maximum Skin Conductance Response (SCR) in Microsiemens (µS) | Arm 1: Hydrocortisone | Fear Conditioning: Beginning | .0325522 | Standard Error .0351212 | proportion of max SCR (µS) |
| Proportion of Maximum Skin Conductance Response (SCR) in Microsiemens (µS) | Arm 2: D-Cycloserine | Fear Conditioning: Beginning | .0245775 | Standard Error .0367306 | proportion of max SCR (µS) |
| Proportion of Maximum Skin Conductance Response (SCR) in Microsiemens (µS) | Arm 3: Placebo | Fear Conditioning: Beginning | -.0181339 | Standard Error .0328529 | proportion of max SCR (µS) |
| Proportion of Maximum Skin Conductance Response (SCR) in Microsiemens (µS) | Arm 1: Hydrocortisone | Fear Conditioning: End | .1233174 | Standard Error .0351212 | proportion of max SCR (µS) |
| Proportion of Maximum Skin Conductance Response (SCR) in Microsiemens (µS) | Arm 2: D-Cycloserine | Fear Conditioning: End | .1024914 | Standard Error .0367306 | proportion of max SCR (µS) |
| Proportion of Maximum Skin Conductance Response (SCR) in Microsiemens (µS) | Arm 3: Placebo | Fear Conditioning: End | .1276977 | Standard Error .0328529 | proportion of max SCR (µS) |
| Proportion of Maximum Skin Conductance Response (SCR) in Microsiemens (µS) | Arm 1: Hydrocortisone | Fear Extinction: Beginning | .0298132 | Standard Error .0313355 | proportion of max SCR (µS) |
| Proportion of Maximum Skin Conductance Response (SCR) in Microsiemens (µS) | Arm 2: D-Cycloserine | Fear Extinction: Beginning | .0674658 | Standard Error .0327715 | proportion of max SCR (µS) |
| Proportion of Maximum Skin Conductance Response (SCR) in Microsiemens (µS) | Arm 3: Placebo | Fear Extinction: Beginning | .1104578 | Standard Error .0313355 | proportion of max SCR (µS) |
| Proportion of Maximum Skin Conductance Response (SCR) in Microsiemens (µS) | Arm 1: Hydrocortisone | Fear Extinction: End | .0013351 | Standard Error .0313355 | proportion of max SCR (µS) |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 results by groupParticipant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Arm 1: Hydrocortisone | 37 | |
| Overall Study | STARTED | Arm 2: D-Cycloserine | 34 | |
| Overall Study | STARTED | Arm 3: Placebo | 35 | |
| Overall Study | COMPLETED | Arm 1: Hydrocortisone | 37 | |
| Overall Study | COMPLETED | Arm 2: D-Cycloserine | 32 | |
| Overall Study | COMPLETED | Arm 3: Placebo | 35 | |
| Overall Study | NOT COMPLETED | Arm 1: Hydrocortisone | 0 | |
| Overall Study | NOT COMPLETED | Arm 2: D-Cycloserine | 2 | |
| Overall Study | NOT COMPLETED | Arm 3: Placebo | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Arm 1: Hydrocortisone | 0 | 37 |
| Total, all-cause mortality | Arm 2: D-Cycloserine | 0 | 32 |
| Total, all-cause mortality | Arm 3: Placebo | 0 | 35 |
| Total, other adverse events | Arm 1: Hydrocortisone | 0 | 37 |
| Total, other adverse events | Arm 2: D-Cycloserine | 0 | 32 |
| Total, other adverse events | Arm 3: Placebo | 0 | 35 |
| Total, serious adverse events | Arm 1: Hydrocortisone | 0 | 37 |
| Total, serious adverse events | Arm 2: D-Cycloserine | 0 | 32 |
| Total, serious adverse events | Arm 3: Placebo | 0 | 35 |
Source ClinicalTrials.gov
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00674570
GET https://conductscience.org/api/trials/v1/NCT00674570/registered